Citing projections that by 2030, America’s senior population will reach 20 percent of the population – 78 million people – and new survey information showing that Americans feel increasingly helpless about their personal cancer risk as they grow older, the American Institute for Cancer Research (AICR) today highlighted the emerging research showing that even in later life, many cancers can be delayed or prevented through regular physical activity and a plant-based diet.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/aicr/46620/
On World Cancer Day, new independent evidence confirms that the increasing global trend of unhealthy and sedentary lifestyles is responsible for putting millions at an unnecessarily high risk of cancer.
New estimates released today by the World Cancer Research Fund (WCRF) global network suggest that across a range of countries, making lifestyle changes including maintaining a healthy weight, eating a healthy diet and taking regular physical activity can reduce the risk of common cancers by up to a third.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/worldcancerday/47592/
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Stiefel, a GSK company, announced today that Hats On For Skin Health, its global campaign with the International League of Dermatological Societies (ILDS), has raised enough funds to produce 15,000 sun-protective hats for albinos living in East Africa and has already distributed more than 2,000 hats. The hats are being distributed from Tanzania, where estimates are that 98 percent of albino children will die before the age of 40 from cancers of the skin – a direct result of the sun’s damaging rays. Worldwide, albinism affects about one in 20,000 people. However the incidence of albinism in Sub-Saharan Africa is significantly higher than in the rest of the world, specifically in Tanzania where the incidence is one in 1,429.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55030-stiefel-gsk-ilds-hats-on-for-skin-health-campaign-east-africa
More than 12,000 cyclers gathered in ten cities across the country in February and early March to raise more than $13.8 million to support rare cancer research at Memorial Sloan-Kettering Cancer Center. The events took place at Equinox clubs in New York City; Los Angeles; San Francisco; Washington, D.C.; Chicago; Greenwich, Connecticut; Miami; Summit, New Jersey; Long Island; and Boston; bringing together a nationwide network of friends, colleagues, caregivers, and cancer survivors to cycle in solidarity in the battle against rare cancers.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60687-memorial-sloan-kettering-cancer-center-cycle-for-survival-event
Phiten, the pioneer of AQUA-METAL™ materials and innovator of metal-infused technology, and professional baseball players C.J. Wilson, Josh Hamilton and J.B. Shuck have teamed up with Be The Match, the nonprofit organization dedicated to helping patients with blood cancers receive life-saving bone marrow and umbilical cord blood transplants. To support Be The Match and raise awareness of the national Be The Match Registry®, Phiten has designed a limited edition Phiten x Be The Match Tornado Necklace with sales benefiting the cause, and the three pro baseball players have been named Ambassadors of Hope by Be The Match.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64376-phiten-and-mlb-players-for-be-the-match-bone-marrow-donor-registry
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
There’s no doubt about it: having balanced nutrition is a primary key to achieving and maintaining overall health. Healthy eating keeps the body running properly and can prevent a multitude of ills from heart disease and obesity to certain types of cancers. With all the noise out there regarding healthy eating, it can overwhelm even the most diligent person from creating a plan that works.
Registered dietician and best-selling author Frances Largeman-Roth has made a career of helping people transform their eating habits and kitchens. She understands how to help instill changes that work in any household.
Cycle for Survival, the national movement to beat rare cancers, completed its annual series of rides in March. Indoor cycling instructors from Equinox led rides in 13 cities across the country, with over 21,500 participants at the inspiring, high-energy events.
2015 marked a record-breaking year in fundraising, participants, and supporters. Nine years after the first event, Cycle for Survival is the fastest-growing athletic fundraising event,* and raised $25 million from more than 150,000 supporters.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7484551-cycle-for-survival/
Cycle for Survival, the nationwide movement to beat rare cancers, brought hundreds of supporters to Times Square on Friday for its second annual Times Square Takeover, an all-day celebration featuring high-energy stationary cycling sessions.
The day kicked off Cycle for Survival’s ninth year and the launch of registration for its 2015 events across the country.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325451-cycle-for-survival-second-annual-times-square-takeover-2015-registration-launch/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
